Accéder au contenu
Merck
  • A large genomic deletion leads to enhancer adoption by the lamin B1 gene: a second path to autosomal dominant adult-onset demyelinating leukodystrophy (ADLD).

A large genomic deletion leads to enhancer adoption by the lamin B1 gene: a second path to autosomal dominant adult-onset demyelinating leukodystrophy (ADLD).

Human molecular genetics (2015-02-24)
Elisa Giorgio, Daniel Robyr, Malte Spielmann, Enza Ferrero, Eleonora Di Gregorio, Daniele Imperiale, Giovanna Vaula, Georgios Stamoulis, Federico Santoni, Cristiana Atzori, Laura Gasparini, Denise Ferrera, Claudio Canale, Michel Guipponi, Len A Pennacchio, Stylianos E Antonarakis, Alessandro Brussino, Alfredo Brusco
RÉSUMÉ

Chromosomal rearrangements with duplication of the lamin B1 (LMNB1) gene underlie autosomal dominant adult-onset demyelinating leukodystrophy (ADLD), a rare neurological disorder in which overexpression of LMNB1 causes progressive central nervous system demyelination. However, we previously reported an ADLD family (ADLD-1-TO) without evidence of duplication or other mutation in LMNB1 despite linkage to the LMNB1 locus and lamin B1 overexpression. By custom array-CGH, we further investigated this family and report here that patients carry a large (∼660 kb) heterozygous deletion that begins 66 kb upstream of the LMNB1 promoter. Lamin B1 overexpression was confirmed in further ADLD-1-TO tissues and in a postmortem brain sample, where lamin B1 was increased in the frontal lobe. Through parallel studies, we investigated both loss of genetic material and chromosomal rearrangement as possible causes of LMNB1 overexpression, and found that ADLD-1-TO plausibly results from an enhancer adoption mechanism. The deletion eliminates a genome topological domain boundary, allowing normally forbidden interactions between at least three forebrain-directed enhancers and the LMNB1 promoter, in line with the observed mainly cerebral localization of lamin B1 overexpression and myelin degeneration. This second route to LMNB1 overexpression and ADLD is a new example of the relevance of regulatory landscape modifications in determining Mendelian phenotypes.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Chlorure de sodium, for molecular biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
Acide chlorhydrique solution, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Chlorure de sodium solution, 5 M in H2O, BioReagent, for molecular biology, suitable for cell culture
Sigma-Aldrich
Chlorure de sodium solution, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
Désoxycholate de sodium, BioXtra, ≥98.0% (dry matter, NT)
Sigma-Aldrich
Chlorure de sodium, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
Acide chlorhydrique, 36.5-38.0%, BioReagent, for molecular biology
Sigma-Aldrich
Chlorure de sodium, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
Désoxycholate de sodium, ≥97% (titration)
SAFC
Chlorure de sodium solution, 5 M
Supelco
Acide chlorhydrique solution, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
Chlorure de sodium solution, BioUltra, for molecular biology, ~5 M in H2O
Sigma-Aldrich
Chlorure de sodium, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
Hydrogen chloride, ReagentPlus®, ≥99%
SAFC
Désoxycholate de sodium
Sigma-Aldrich
Deoxycholic acid, ≥98% (HPLC)
Sigma-Aldrich
Acide chlorhydrique solution, ~6 M in H2O, for amino acid analysis
Sigma-Aldrich
Chlorure d'hydrogène solution, 3 M in cyclopentyl methyl ether (CPME)
Sigma-Aldrich
Acide chlorhydrique solution, 32 wt. % in H2O, FCC
Sigma-Aldrich
Deoxycholic acid, ≥99.0% (T)
Sigma-Aldrich
Sodium chloride-35Cl, 99 atom % 35Cl
Sigma-Aldrich
Chlorure de sodium solution, 0.85%
Sigma-Aldrich
Bicinchoninic acid disodium salt hydrate, ≥98% (HPLC)